

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous claims, and listings of claims, in the application.

Claim 1 (Cancelled).

Claim 2 (Currently Amended): The hyaluronic acid modification product according to claim 1 ~~3~~, wherein said block polymer is a polyethylene oxide-polypropylene oxide-polyethylene oxide block polymer or a polypropylene oxide-polyethylene oxide-polypropylene oxide block polymer.

Claim 3 (Currently Amended): ~~The hyaluronic acid modification product according to claim 1~~ A hyaluronic acid modification product, in which hyaluronic acid and/or a pharmaceutically acceptable salt thereof is covalently bound to a block polymer, selected from polyethylene oxide-polypropylene oxide-polyethylene oxide block polymer, polypropylene oxide-polyethylene oxide-polypropylene oxide block polymer, polyethylene oxide-poly(lactic acid)/polyglycolic acid copolymer-polyethylene oxide block polymer, poly(lactic acid)/polyglycolic acid copolymer-polyethylene oxide-poly(lactic acid)/polyglycolic acid copolymer block polymer, polyethylene oxide-poly(lactic acid)-polyethylene oxide block polymer and poly(lactic acid)-polyethylene oxide-poly(lactic acid) block polymer wherein the phase transition temperature of said hyaluronic acid modification product in physiological saline and/or phosphate physiological saline

acid/polyglycolic acid copolymer-polyethylene oxide block polymer, polylactic acid/polyglycolic acid copolymer- polyethylene oxide-polylactic acid/polyglycolic acid copolymer block polymer, polyethylene oxide-polylactic acid-polyethylene oxide block polymer and polylactic acid-polyethylene oxide-polylactic acid block polymer wherein the phase transition temperature of said hyaluronic acid modification product in physiological saline and/or phosphate physiological saline is in the range from 20°C to 35°C when the concentration of said hyaluronic acid modification product is 10% w/v or less, wherein the weight average molecular weight of said hyaluronic acid and/or a pharmaceutically acceptable salt thereof is 1,500,000 daltons or less.

Claim 10 (Currently Amended): A pharmaceutical composition comprising the hyaluronic acid modification product according to claim + 3 as an active ingredient.

Claim 11 (Cancelled).

Claim 12 (Currently Amended): The pharmaceutical preparation for treating joint diseases comprising the hyaluronic acid modification product according to claim + 3 as an active ingredient, wherein the joint disease is loss of articular cartilage, rheumatoid arthritis, osteoarthritis or scapulo-humeral peri arthritis.

Claim 21 (Original): The tissue repairing agent according to claim 20, which is used for repairing damage to soft tissue, atrophic irregularity after surgical operation, damage caused by Mohs' chemosurgical treatment, wrinkles or laceration scars in wrinkles.

Claim 22 (Cancelled).

Claim 23 (Cancelled).